Enpatoran Phase 2 Trial Reports Symptom Improvement in Cutaneous Lupus
An oral TLR7/8 inhibitor met its Phase 2 primary endpoint in cutaneous lupus erythematosus, per a Dermatology Advisor report, though full efficacy data remain unpublished.
Topic
Autoimmune Skin Disease
Topic
Autoimmune Skin Disease
Plasma EV miR-148a-3p Tied to Plasmablast Surge in Bullous Pemphigoid
Plasma extracellular vesicles from bullous pemphigoid patients shuttle miR-148a-3p into B cells, where it represses BACH2 and act…